According to the most recent check, shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) are seeing a massive spike today, rising 34.78% on the charts to $2.01. A pivotal investor call featuring Dr. Ehab Atallah, a professor of medicine at the Medical College of Wisconsin and the principal investigator of the Actimab-A + CLAG-M combination trial in patients with relapsed or refractory acute myeloid leukemia (r/r AML), was held at the same time as the notable increase.
Perspectives on Clinical Advancements and Actimab-A
Dr. Atallah discussed Actimab-A’s clinical development during the event, including long-term survival statistics and strategies for an upcoming Phase 2/3 pivotal study in r/r AML. Trials carried out under Actinium’s cooperative research and development agreement (CRADA) with the National Cancer Institute (NCI) were also discussed. The management team of ATNM also explained its recently launched Actimab-A solid tumor program, which aims to increase the use of its targeted radiotherapies.
Growing Oncology Market Potential
Three significant multibillion-dollar market prospects for ATNM’s targeted radiotherapies were highlighted in the company’s most recent reports. One of them is Actimab-A, which may be used in a variety of therapeutic scenarios as a mutation-agnostic backbone therapy for myeloid malignancies, such as AML and myelodysplastic syndromes (MDS).
Another key area of focus is Actimab-A’s potential in treating solid tumors by combining with PD-1 inhibitors such as KEYTRUDA and OPDIVO. Additionally, Actinium is advancing Iomab-ACT as a universal targeted conditioning agent to enhance access to cell and gene therapies and improve patient outcomes.
Strategic Partnership to Ensure Supply of Actinium-225
In order to ensure a consistent supply of Actinium-225 (Ac-225), ATNM has signed a supply deal with Eckert & Ziegler, further bolstering its R&D efforts. Actimab-A and other pipeline candidates will continue to be developed in both domestic and foreign clinical trials with the help of this crucial component.
Actinium continues to lead the way in targeted radiotherapy innovation as Actimab-A advances into pivotal studies for r/r AML in frontline settings under the NCI cooperation. ATNM is positioned as a global leader in meeting important unmet cancer requirements thanks to its fortified supply chain and foray into solid tumor therapies.